Westover Capital Advisors’s AbbVie ABBV Stock Holding History

Westover Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.86M	Sell	8,560 -216	-2%	-$47.9K	0.34%	62
2025 Q4	$2.01M	Sell	8,776 -37	-0.4%	-$8.43K	0.37%	57
2025 Q3	$2.04M	Sell	8,813 -100	-1%	-$20.4K	0.38%	58
2025 Q2	$1.65M	Sell	8,913 -3	-0%	-$558	0.33%	66
2025 Q1	$1.87M	Sell	8,916 -2,417	-21%	-$470K	0.41%	53
2024 Q4	$2.01M	Sell	11,333 -41	-0.4%	-$7.54K	0.44%	53
2024 Q3	$2.25M	Sell	11,374 -300	-3%	-$56K	0.43%	48
2024 Q2	$2M	Buy	11,674 +2,696	+30%	+$447K	0.52%	53
2024 Q1	$1.63M	Sell	8,978 -192	-2%	-$33.1K	0.48%	57
2023 Q4	$1.42M	Buy	9,170 +380	+4%	+$55.4K	0.46%	55
2023 Q3	$1.31M	Sell	8,790 -630	-7%	-$92.5K	0.47%	50
2023 Q2	$1.27M	Sell	9,420 -18	-0.2%	-$2.64K	0.44%	58
2023 Q1	$1.5M	Sell	9,438 -2	-0%	-$306	0.56%	53
2022 Q4	$1.53M	Sell	9,440 -10	-0.1%	-$1.53K	0.6%	50
2022 Q3	$1.27M	Sell	9,450 -1,321	-12%	-$190K	0.48%	57
2022 Q2	$1.65M	Buy	10,771 +4,085	+61%	+$624K	0.61%	47
2022 Q1	$1.08M	Buy	6,686 +111	+2%	+$16.1K	0.34%	66
2021 Q4	$890K	Sell	6,575 -1,160	-15%	-$137K	0.26%	78
2021 Q3	$834K	Buy	7,735 +267	+4%	+$30.5K	0.26%	82
2021 Q2	$841K	Sell	7,468 -208	-3%	-$23.4K	0.27%	79
2021 Q1	$831K	Sell	7,676 -162	-2%	-$17.3K	0.29%	76
2020 Q4	$840K	Sell	7,838 -768	-9%	-$73.8K	0.3%	75
2020 Q3	$754K	Buy	8,606 +136	+2%	+$12.8K	0.31%	74
2020 Q2	$832K	Sell	8,470 -60	-0.7%	-$5.28K	0.39%	68
2020 Q1	$650K	Buy	8,530 +632	+8%	+$53.8K	0.35%	64
2019 Q4	$699K	Sell	7,898 -15,337	-66%	-$1.27M	0.31%	72
2019 Q3	$1.76M	Sell	23,235 -6,827	-23%	-$468K	0.83%	41
2019 Q2	$2.19M	Sell	30,062 -1,655	-5%	-$130K	1.08%	35
2019 Q1	$2.56M	Sell	31,717 -2,474	-7%	-$202K	1.33%	28
2018 Q4	$3.15M	Sell	34,191 -5,942	-15%	-$523K	1.97%	14
2018 Q3	$3.8M	Sell	40,133 -1,031	-3%	-$97.8K	1.92%	15
2018 Q2	$3.81M	Buy	41,164 +17,245	+72%	+$1.68M	2.06%	13
2018 Q1	$2.26M	Buy	23,919 +1,205	+5%	+$132K	1.23%	35
2017 Q4	$2.2M	Buy	22,714 +2,280	+11%	+$215K	1.21%	29
2017 Q3	$1.82M	Buy	20,434 +383	+2%	+$29.2K	1.07%	34
2017 Q2	$1.45M	Buy	20,051 +9,907	+98%	+$666K	0.96%	37
2017 Q1	$661K	Buy	10,144 +388	+4%	+$24.4K	0.44%	63
2016 Q4	$611K	Sell	9,756 -8,377	-46%	-$511K	0.44%	58
2016 Q3	$1.14M	Buy	18,133 +1,989	+12%	+$129K	0.85%	39
2016 Q2	$999K	Buy	16,144 +4,041	+33%	+$246K	0.82%	41
2016 Q1	$691K	Buy	12,103 +4,386	+57%	+$244K	0.58%	48
2015 Q4	$457K	Sell	7,717 -1,160	-13%	-$66.8K	0.38%	66
2015 Q3	$483K	Sell	8,877 -3,922	-31%	-$255K	0.42%	61
2015 Q2	$860K	Buy	12,799 +5,074	+66%	+$331K	0.68%	44
2015 Q1	$452K	Sell	7,725 -2,791	-27%	-$169K	0.37%	66
2014 Q4	$688K	Sell	10,516 -746	-7%	-$47K	0.59%	50
2014 Q3	$650K	Sell	11,262 -12,691	-53%	-$705K	0.53%	58
2014 Q2	$1.35M	Sell	23,953 -18,973	-44%	-$995K	1.14%	34
2014 Q1	$2.21M	Buy	42,926 +53	+0.1%	+$2.68K	2.06%	17
2013 Q4	$2.26M	Sell	42,873 -1,114	-3%	-$54.8K	2.16%	16
2013 Q3	$1.97M	Sell	43,987 -7,559	-15%	-$335K	2.04%	20
2013 Q2	$2.13M	Buy	+51,546	New	+$2.25M	2.09%	20

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westover Capital Advisors's ABBV Position: Q1 2026 in Review

Westover Capital Advisors reduced its AbbVie (ABBV) stake by 2.5% in Q1 2026, selling an estimated $47.9K and leaving 8,560 shares worth $1.86M. The position accounts for 0.34% of the portfolio, ranked #62.

Westover Capital Advisors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.81M in Q2 2018. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Westover Capital Advisors held 8,560 shares of AbbVie worth $1.86M as of Q1 2026.
Westover Capital Advisors sold 216 AbbVie shares in Q1 2026, an estimated $47.9K.
AbbVie made up 0.34% of Westover Capital Advisors's portfolio in Q1 2026, its #62 holding.
Westover Capital Advisors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Westover Capital Advisors's AbbVie position peaked at $3.81M in Q2 2018.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Westover Capital Advisors's 13F filing for Q1 2026, filed 5 May 2026.